Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Norfloxacin

Research Leaders

7 sponsors active, led by Soon Chun Hyang University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT02436798CompletedPrimary

5-HT3 Antagonists (Antiemetics) and Cardiac Safety

NCT01542801Phase 4CompletedPrimary

Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention

NCT01957839Phase 4CompletedPrimary

Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

Showing all 3 trials

Research Network

Common Treatments

  • Norfloxacin1
  • Cabergoline1
  • Ciprofloxacin1
  • Ondansetron1

Active Sponsors

  • Soon Chun Hyang University1
  • Canadian Institutes of Health Research (CIHR)1
  • Istanbul Bakirkoy Maternity and Children Diseases Hospital1
  • Korea University1
  • Kyungpook National University Hospital1

Top Investigators

Activity Timeline